Wakutsu, Naohiko http://orcid.org/0000-0002-7925-9669
Hirose, Emi http://orcid.org/0000-0002-5254-6094
Yonemoto, Naohiro
Demiya, Sven
Funding for this research was provided by:
Pfizer Japan
Article History
Accepted: 4 December 2022
First Online: 17 January 2023
Declarations
:
: Pfizer Japan Inc. was the only direct sponsor of this study and fees were paid to IQVIA Solutions Japan K.K.
: Naohiko Wakutsu received an advisory fee from Pfizer Japan Inc. Emi Hirose and Naohiro Yonemoto are full-time employees of Pfizer Japan Inc. and stockholders in Pfizer Inc. Sven Demiya is a full-time employee of IQVIA Solutions Japan K.K. This SLR used I2E Enterprise software from Linguamatics, which is a proprietary Natural Language Processing (NLP) software.
: The dataset used for the review was gathered from various database domains of agencies and hence is publicly available; it is also available from the corresponding author upon submission of a reasonable request.
: Initial content was derived using the I2E Enterprise software from Linguamatics (ExternalRef removed; UK), and no additional software code was developed. Additional information can be provided upon submission of a reasonable request.
: The study does not involve human participants; no ethical approval is required.
: Not applicable.
: Not applicable.
: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work, and have given final approval for this version of the manuscript to be published. All named authors contributed to the study design, data extraction, and reviewing of the manuscript. None of the authors were involved in the literature searching process.